1. Home
  2. NRSN
  3. NRSN News

Latest NeuroSense Therapeutics Ltd. (NRSN) News on July 26, 2024

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

PR Newswire

17 days ago

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

Zacks Small Cap Research

9 months ago

DYAI: Third Quarter Update

Associated Press Finance

9 months ago

Priority Technology: Q3 Earnings Snapshot

Associated Press Finance

9 months ago

Sangamo: Q3 Earnings Snapshot

Share on Social Networks: